MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
MYRIAD GENETICS INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | – | – | – | – | $45.10M | $61.70M | $53.30M | $49.30M | $48.10M | $27.60M | – | – |
| Diagnostics | – | – | – | – | $593.50M | $789.40M | $690.40M | $679.40M | $692.40M | $695.50M | – | – |
| Diagnostic | – | – | – | – | $593.50M | $789.40M | $690.40M | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | – | – | – | – | -$149.30M | -$125.70M | -$20.70M | -$80.70M | -$72.50M | -$82.90M | – |
| Diagnostics | – | – | – | – | -$82.40M | $133.30M | $142.60M | $124.70M | $225.90M | $217.10M | – |
| Diagnostic | – | – | – | – | -$82.40M | $133.30M | $142.60M | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hereditary Cancer | $372.40M | $364.50M | $327.80M | $305.50M | – | – | – | – | – | – | 45.2% | +2.2% |
| Prenatal | $186.30M | $177.10M | $151.30M | $116.40M | – | – | – | – | – | – | 22.6% | +5.2% |
| Mental Health | $144.10M | $170.20M | $138.50M | – | – | – | – | – | – | – | 17.5% | -15.3% |
| Tumor Profiling | $121.70M | $125.80M | $135.60M | $128.60M | $48.30M | – | – | – | – | – | 14.8% | -3.3% |
| Molecular diagnostic testing | – | – | – | – | $586.90M | $789.40M | $690.40M | $679.40M | $692.40M | $694.90M | – | – |
| Pharmaceutical and clinical services | – | – | – | – | $51.70M | $61.70M | $53.30M | $49.30M | $48.10M | $27.60M | – | – |
| Other | – | – | – | – | $1.30M | $900.00K | $3.50M | $11.50M | – | – | – | – |
| Molecular diagnostic - Prolaris | – | – | – | – | $24.70M | $25.50M | $21.50M | $11.10M | – | – | – | – |
| Molecular diagnostic - GeneSight | – | – | – | – | $74.10M | $112.60M | $124.90M | $78.40M | – | – | – | – |
| Hereditary Cancer | – | – | – | – | $347.40M | $479.70M | $471.40M | $525.50M | – | – | – | – |
| Molecular diagnostic - EndoPredict | – | – | – | – | $10.50M | $10.40M | $8.80M | $7.70M | – | – | – | – |
| Molecular diagnostic - Vectra | – | – | – | – | $39.10M | $48.30M | $55.20M | $45.20M | – | – | – | – |
| Prenatal | – | – | – | – | $76.70M | $104.90M | $0 | – | – | – | – | – |
| Molecular diagnostic - myChoice CDx | – | – | – | – | $13.10M | $7.10M | $5.10M | – | – | – | – | – |
| Tumor Profiling | – | – | – | – | $48.30M | $43.00M | – | – | – | – | – | – |
| Pharmacogenomics | – | – | – | – | $74.10M | $112.60M | – | – | – | – | – | – |
| Autoimmune | – | – | – | – | $39.10M | $48.30M | – | – | – | – | – | – |
| Testing Revenue | – | – | $753.20M | $678.40M | $586.90M | – | – | – | – | – | – | – |
| Other revenue | – | – | $0 | $0 | $51.70M | – | – | – | – | – | – | – |
| Autoimmune | – | $0 | $0 | $300.00K | $39.10M | – | – | – | – | – | – | – |
| Pharmacogenomics | – | $170.20M | $138.50M | $127.60M | $74.10M | – | – | – | – | – | – | – |
| Other | – | – | $0 | $0 | $1.30M | – | – | – | – | – | – | – |
| Prenatal | – | – | $151.30M | $116.40M | $76.70M | – | – | – | – | – | – | – |
| Hereditary Cancer | – | – | $327.80M | $305.50M | $347.40M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $768.00M | $769.50M | $671.70M | $591.50M | $596.20M | $805.40M | $700.50M | – | – | – | 93.1% | -0.2% |
| RoW | $56.50M | $68.10M | $81.50M | $86.90M | $42.40M | $45.70M | $43.20M | – | – | – | 6.9% | -17.0% |
From the segment and revenue-disaggregation notes of Myriad Genetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.